<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366548</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-009</org_study_id>
    <nct_id>NCT00366548</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine manufactured with Polysorbate 80 compared
      to a 13-valent pneumococcal conjugate (13vPnC) manufactured without Polysorbate 80 when given
      concomitantly with routine paediatric vaccinations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series</measure>
    <time_frame>One month after 3-dose infant series (at 5 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) in 13vPnC+P80 Group Relative to 13vPnC-P80 Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (at 5 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</measure>
    <time_frame>one month after the toddler dose (at 13 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</measure>
    <time_frame>one month after the toddler dose (at 13 months of age)</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent pneumococcal conjugate vaccine with Polysorbate 80</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent pneumococcal conjugate vaccine without Polysorbate 80</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Aged 2 months (42 through 98 days) at the time of enrollment.

          2. Available for the entire study period and whose parent(s)/legal guardian(s) could be
             reached by telephone.

          3. In good health as determined by medical history, physical examination, and judgment of
             the investigator.

          4. Parent(s)/legal guardian(s) were able to complete all relevant study procedures during
             study participation.

        Exclusion criteria:

          1. Previous vaccination with licensed or investigational pneumococcal vaccine.

          2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, or polio
             vaccines.

          3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis,
             polio, hepatitis B, or pneumococcal vaccines.

          5. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          6. Known or suspected immune deficiency or suppression.

          7. History of culture-proven invasive disease caused by S pneumoniae.

          8. Major known congenital malformation or serious chronic disorder.

          9. Significant neurological disorder or history of seizure (including febrile seizure),
             or significant stable or evolving disorders (such as cerebral palsy, encephalopathy,
             or hydrocephalus), or other significant disorders. This did not include resolving
             syndromes because of birth trauma such as Erb palsy.

         10. Receipt of blood products or γ-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies [eg, Synagis]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Poland, WPWZMED@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-422</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubartow</city>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oborniki Slaskie</city>
        <zip>55-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Infant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Poland from November 2006 to December 2006.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC With (+) Polysorbate 80</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) with (+) P80 coadministered with combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and conjugated Hib antigens (Pentaxim) and hepatitis B recombinant vaccine adsorbed (Engerix-B) at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant series), and combined vaccine containing attenuated measles, mumps, and rubella viruses (Priorix) at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>13vPnC Without (-) Polysorbate 80</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) without (-) P80 coadministered with combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and conjugated Hib antigens (Pentaxim) and hepatitis B recombinant vaccine adsorbed (Engerix-B) at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant series), and combined vaccine containing attenuated measles, mumps, and rubella viruses (Priorix) at 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC With (+) Polysorbate 80</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) with (+) P80 coadministered with combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and conjugated Hib antigens (Pentaxim) and hepatitis B recombinant vaccine adsorbed (Engerix-B) at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant series), and combined vaccine containing attenuated measles, mumps, and rubella viruses (Priorix) at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>13vPnC Without (-) Polysorbate 80</title>
          <description>Participants received one single 0.5mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) without (-) P80 coadministered with combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and conjugated Hib antigens (Pentaxim) and hepatitis B recombinant vaccine adsorbed (Engerix-B) at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant series), and combined vaccine containing attenuated measles, mumps, and rubella viruses (Priorix) at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.5"/>
                    <measurement group_id="B2" value="2.1" spread="0.5"/>
                    <measurement group_id="B3" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (at 5 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + Polysorbate 80 After the Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - Polysorbate 80 After the Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=222,224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="89.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="94.1" lower_limit="90.3" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=145,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="54.4" upper_limit="67.2"/>
                    <measurement group_id="O2" value="66.4" lower_limit="60.0" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=231,232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="94.0" upper_limit="98.8"/>
                    <measurement group_id="O2" value="97.5" lower_limit="94.6" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=225,232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="90.8" upper_limit="97.1"/>
                    <measurement group_id="O2" value="97.5" lower_limit="94.6" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=233,233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O2" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=228,234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.4" upper_limit="98.0"/>
                    <measurement group_id="O2" value="98.3" lower_limit="95.8" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=205,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="81.1" upper_limit="90.3"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.3" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=228,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.4" upper_limit="98.0"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.3" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=233,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=224,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="90.3" upper_limit="96.7"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.3" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=206,205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="81.6" upper_limit="90.6"/>
                    <measurement group_id="O2" value="86.1" lower_limit="81.1" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=235,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="96.4" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=235,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="96.4" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after the toddler dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + Polysorbate 80 After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - Polysorbate 80 After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at the 2 month visit, Pentaxim at the 3 and 4 month visits, and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=225,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=226,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="96.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.7" lower_limit="96.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="96.2" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=223,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="91.3" upper_limit="97.5"/>
                    <measurement group_id="O2" value="94.5" lower_limit="90.8" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=226,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4-days after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + P80 Dose 1 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age(infant series, Dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - P 80 Dose 1 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age (infant series, Dose 1).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC + P80 Dose 2 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 months age (infant series, Dose 2).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC - P80 Dose 2 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 months age (infant series, Dose 2).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC + P80 Dose 3 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series, Dose 3).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC - P80 Dose 3 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series, Dose 3).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC + P80 Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>13vPnC - P80 Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series), and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="249"/>
                <count group_id="O5" value="246"/>
                <count group_id="O6" value="247"/>
                <count group_id="O7" value="240"/>
                <count group_id="O8" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=238,237,228,229,210,216,178,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="32.8"/>
                    <measurement group_id="O5" value="24.8"/>
                    <measurement group_id="O6" value="23.1"/>
                    <measurement group_id="O7" value="42.1"/>
                    <measurement group_id="O8" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Sig (n=235,233,220,221,203,211,160,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="1.5"/>
                    <measurement group_id="O6" value="1.9"/>
                    <measurement group_id="O7" value="2.5"/>
                    <measurement group_id="O8" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=236,239,228,228,210,225,174,181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="30.5"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="36.7"/>
                    <measurement group_id="O6" value="38.2"/>
                    <measurement group_id="O7" value="29.9"/>
                    <measurement group_id="O8" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=236,236,227,226,209,221,169,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="31.9"/>
                    <measurement group_id="O5" value="32.5"/>
                    <measurement group_id="O6" value="33.5"/>
                    <measurement group_id="O7" value="26.6"/>
                    <measurement group_id="O8" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=236,236,224,224,208,217,164,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="11.2"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="13.9"/>
                    <measurement group_id="O6" value="17.5"/>
                    <measurement group_id="O7" value="12.2"/>
                    <measurement group_id="O8" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Severe(n=235,233,220,221,203,211,159,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=238,238,232,231,216,226,178,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="38.8"/>
                    <measurement group_id="O4" value="48.5"/>
                    <measurement group_id="O5" value="46.8"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="42.1"/>
                    <measurement group_id="O8" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=238,235,232,230,215,226,176,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="38.4"/>
                    <measurement group_id="O4" value="47.0"/>
                    <measurement group_id="O5" value="46.5"/>
                    <measurement group_id="O6" value="46.9"/>
                    <measurement group_id="O7" value="35.8"/>
                    <measurement group_id="O8" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=235,232,220,222,206,211,164,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="3.9"/>
                    <measurement group_id="O6" value="9.0"/>
                    <measurement group_id="O7" value="12.8"/>
                    <measurement group_id="O8" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Severe (n=235,231,220,221,203,211,159,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased (decr)appetite, irritability, increased (incr)sleep, decreased sleep, hives, use of medication (meds) to treat symptoms (sx), and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4-days after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + P80 Dose 1 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age(infant series, Dose 1).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - P 80 Dose 1 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age (infant series, Dose 1).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC + P80 Dose 2 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 months age (infant series, Dose 2).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC - P80 Dose 2 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 months age (infant series, Dose 2).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC + P80 Dose 3 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series, Dose 3).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC - P80 Dose 3 Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant series, Dose 3).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC + P80 Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>13vPnC - P80 Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever [Fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased (decr)appetite, irritability, increased (incr)sleep, decreased sleep, hives, use of medication (meds) to treat symptoms (sx), and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="249"/>
                <count group_id="O5" value="246"/>
                <count group_id="O6" value="247"/>
                <count group_id="O7" value="240"/>
                <count group_id="O8" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fv ≥38°C, ≤39°C(n=236,235,224,229,208,218,170,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="18.3"/>
                    <measurement group_id="O4" value="17.0"/>
                    <measurement group_id="O5" value="19.7"/>
                    <measurement group_id="O6" value="20.6"/>
                    <measurement group_id="O7" value="22.9"/>
                    <measurement group_id="O8" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;39°C, ≤40°C(n=235,233,221,221,203,211,162,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="1.0"/>
                    <measurement group_id="O6" value="0.9"/>
                    <measurement group_id="O7" value="2.5"/>
                    <measurement group_id="O8" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;40°C (n=235,233,221,221,203,211,160,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr appetite (n=237,237,221,224,210,222,172,183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="22.4"/>
                    <measurement group_id="O3" value="16.3"/>
                    <measurement group_id="O4" value="24.1"/>
                    <measurement group_id="O5" value="21.4"/>
                    <measurement group_id="O6" value="20.7"/>
                    <measurement group_id="O7" value="26.2"/>
                    <measurement group_id="O8" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=240,239,232,232,215,226,184,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="55.2"/>
                    <measurement group_id="O3" value="51.7"/>
                    <measurement group_id="O4" value="53.9"/>
                    <measurement group_id="O5" value="45.6"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="49.5"/>
                    <measurement group_id="O8" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incr sleep (n=242,242,231,229,209,221,174,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="52.5"/>
                    <measurement group_id="O3" value="35.9"/>
                    <measurement group_id="O4" value="39.3"/>
                    <measurement group_id="O5" value="25.8"/>
                    <measurement group_id="O6" value="27.6"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr sleep (n=238,236,227,227,209,217,170,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="29.7"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="26.4"/>
                    <measurement group_id="O5" value="25.4"/>
                    <measurement group_id="O6" value="24.4"/>
                    <measurement group_id="O7" value="19.4"/>
                    <measurement group_id="O8" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-treat sx (n=236,235,222,226,205,218,172,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="16.6"/>
                    <measurement group_id="O3" value="15.3"/>
                    <measurement group_id="O4" value="16.8"/>
                    <measurement group_id="O5" value="15.1"/>
                    <measurement group_id="O6" value="14.7"/>
                    <measurement group_id="O7" value="21.5"/>
                    <measurement group_id="O8" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds-prevent sx(n=235,234,220,223,205,217,171,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="16.4"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="15.1"/>
                    <measurement group_id="O6" value="10.6"/>
                    <measurement group_id="O7" value="18.7"/>
                    <measurement group_id="O8" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC+P80 Group Relative to 13vPnC-P80 Group After the 3-Dose Infant Series</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (at 5 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + Polysorbate 80 After the Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - Polysorbate 80 After the Infant Series</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC+P80 Group Relative to 13vPnC-P80 Group After the 3-Dose Infant Series</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="1.30" upper_limit="1.65"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.36" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" lower_limit="0.44" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.48" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.34" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.38" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" lower_limit="2.06" upper_limit="2.73"/>
                    <measurement group_id="O2" value="2.48" lower_limit="2.20" upper_limit="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="1.67" upper_limit="2.03"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.71" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.30" upper_limit="1.65"/>
                    <measurement group_id="O2" value="1.75" lower_limit="1.60" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.83" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.11" lower_limit="1.00" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="1.26" upper_limit="1.55"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.32" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.38" upper_limit="1.63"/>
                    <measurement group_id="O2" value="1.62" lower_limit="1.49" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.13" upper_limit="1.40"/>
                    <measurement group_id="O2" value="1.30" lower_limit="1.16" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.88" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.92" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="1.81" upper_limit="2.15"/>
                    <measurement group_id="O2" value="1.89" lower_limit="1.73" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="2.44" upper_limit="2.95"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.69" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 1 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 3 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 5 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6A the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 7F the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19A the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>one month after the toddler dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate IgG antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + Polysorbate 80 After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at approximately 2 months of age, Pentaxim at approximately 3 months and 4 months of age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC - Polysorbate 80 After Toddler Dose</title>
            <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at the 2 month visit, Pentaxim at the 3 and 4 month visits, and Priorix at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity population had valid and determinate assay results, and had no other major protocol violations, (n) = number of participants with a determinate IgG antibody concentration for the specified serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" lower_limit="4.65" upper_limit="5.92"/>
                    <measurement group_id="O2" value="5.38" lower_limit="4.78" upper_limit="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=221,228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" lower_limit="8.70" upper_limit="11.23"/>
                    <measurement group_id="O2" value="10.65" lower_limit="9.40" upper_limit="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.73" upper_limit="3.31"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.80" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=224,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.72" lower_limit="10.26" upper_limit="13.40"/>
                    <measurement group_id="O2" value="11.95" lower_limit="10.42" upper_limit="13.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" lower_limit="3.06" upper_limit="3.78"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.79" upper_limit="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=223,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" lower_limit="8.45" upper_limit="10.97"/>
                    <measurement group_id="O2" value="10.27" lower_limit="8.99" upper_limit="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=223,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.44" upper_limit="4.38"/>
                    <measurement group_id="O2" value="4.15" lower_limit="3.73" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" lower_limit="5.36" upper_limit="6.78"/>
                    <measurement group_id="O2" value="6.11" lower_limit="5.43" upper_limit="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=213,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.99" upper_limit="1.20"/>
                    <measurement group_id="O2" value="1.16" lower_limit="1.05" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=225,234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="3.41" upper_limit="4.23"/>
                    <measurement group_id="O2" value="3.98" lower_limit="3.59" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=224,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" lower_limit="6.66" upper_limit="8.40"/>
                    <measurement group_id="O2" value="8.19" lower_limit="7.38" upper_limit="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=226,238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" lower_limit="4.89" upper_limit="5.88"/>
                    <measurement group_id="O2" value="4.95" lower_limit="4.50" upper_limit="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=224,236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.20" lower_limit="11.88" upper_limit="14.67"/>
                    <measurement group_id="O2" value="13.02" lower_limit="11.88" upper_limit="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC + P80 Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E2">
          <title>13vPnC - P 80 Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E3">
          <title>13vPnC + P80 Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E4">
          <title>13vPnC - P80 Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E5">
          <title>13vPnC + P80 Toddler Dose</title>
          <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E6">
          <title>13vPnC - P80 Toddler Dose</title>
          <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E7">
          <title>13vPnC + P80 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 13vPnC + P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E8">
          <title>13vPnC - P80 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 13vPnC - P80 coadministered with Pentaxim and Engerix-B at 2 months of age, Pentaxim at 3 and 4 months age (infant doses), and Priorix at 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Alloimmunisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Meningitis meningococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Limbic traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ultrasound kidney abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="111" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Craniotabes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Brachycephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="235"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="170"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="172"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="172"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="170"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="182"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="184"/>
                <counts group_id="E6" subjects_affected="111" subjects_at_risk="198"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur functional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Skin inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="188"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="63" subjects_at_risk="181"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="169"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="178"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3;Induration (mild)</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="182"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="171"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (Any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="104" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Any)</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Any)</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="176"/>
                <counts group_id="E6" subjects_affected="90" subjects_at_risk="194"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="173"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

